It hasn't been the best quarter for DexCom, Inc. (NASDAQ:DXCM) shareholders, since the share price has fallen 18% in that time. But that scarcely detracts from the really solid long term returns ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

SAN DIEGO, May 01, 2025--Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program ...

Now, it’s worth noting Stock Advisor’s total average return is 984 % — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose ...

At long last, Dexcom's Share app, which allows users to view and share data from their G5 continuous glucose monitors, will be available for Android users. The Android app just now received FDA ...

Dexcom Share, a cradle device that will allow users to send data from a Dexcom continuous glucose monitor to multiple smartphones, has received 510(k) clearance from the FDA. The system is designed to ...

The medical device maker has already made impressive gains. A planned stock split may make shares even more attractive to investors. DexCom's robust business performance is reflected in its surging ...

Dexcom marked a milestone Friday after it became the first company to get FDA pre-market approval for its mobile apps to support continuous glucose monitoring. It is part of a larger push to make it ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...